Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Theratechnologies Inc.
Theratechnologies Inc. News
Jan 9, 2025 - globenewswire.com
Theratechnologies Provides Update on EGRIFTA SV® Supply
Dec 18, 2024 - globenewswire.com
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Dec 10, 2024 - globenewswire.com
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Dec 9, 2024 - globenewswire.com
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
Theratechnologies Inc. Quantitative Score
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Theratechnologies Inc. Earnings & Revenue
Theratechnologies Inc. Financials
Table Compare
Compare THTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | THTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | THTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | THTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | THTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Theratechnologies Inc. Income
Theratechnologies Inc. Balance Sheet
Theratechnologies Inc. Cash Flow
Theratechnologies Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Theratechnologies Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Theratechnologies Inc. Executives
| Name | Role |
|---|---|
| Mr. Paul Lévesque | President, Chief Executive Officer & Director |
| Dr. Christian Marsolais Ph.D. | Senior Vice President & Chief Medical Officer |
| Mr. Philippe Dubuc M.B.A., MBA | Senior Vice President & Chief Financial Officer |
| Mr. John Leasure | Global Commercial Officer |
| Mr. Jocelyn Lafond L.L.M., LL.B. | General Counsel & Corporate Secretary |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Paul Lévesque | President, Chief Executive Officer & Director | Male | 1964 | 1.18M |
| Dr. Christian Marsolais Ph.D. | Senior Vice President & Chief Medical Officer | 1963 | 434.61K | |
| Mr. Philippe Dubuc M.B.A., MBA | Senior Vice President & Chief Financial Officer | Male | 1967 | 432.31K |
| Mr. John Leasure | Global Commercial Officer | Male | 1965 | 420.91K |
| Mr. Jocelyn Lafond L.L.M., LL.B. | General Counsel & Corporate Secretary | Male | 1968 | 316.29K |